Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase NA 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

pembrolizumab 120Carboplatin 114Pemetrexed 74Cisplatin 71Nivolumab 68Paclitaxel 58Docetaxel 56Radiotherapy 41Erlotinib Hydrochloride 41Gemcitabine 35Etoposide 34atezolizumab 30osimertinib 29Cetuximab 27Ipilimumab 25Bevacizumab 25Radiosurgery 22durvalumab 21Cyclophosphamide 20Drug Therapy 18130-nm albumin-bound paclitaxel 17avelumab 14Taxes 14Gefitinib 14Albumin-Bound Paclitaxel 14Irinotecan 13Injections 13fludarabine 11Radiation 11cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × dupilumab × Thoracic × Clear all
NCT05013450 2025-12-17

Dupilumab_Metastatic NSCLC

Icahn School of Medicine at Mount Sinai

Phase 1/2 Active not recruiting
33 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06088771 2025-05-08

Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC

Icahn School of Medicine at Mount Sinai

Phase 1/2 Recruiting
21 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡